Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tania Jain

Showing results (41-50 of 118) with videos related to

Pageof 12
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|July 14, 2015
BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple MyelomaMuthu Veeraputhiran, Tania Jain, Abhinav Deol, et al.
Leukemia & Lymphoma|April 14, 2020
Clinical outcomes with low dose anti-thymocyte globulin in patients undergoing matched unrelated donor allogeneic hematopoietic cell transplantationLuke Mountjoy, Tania Jain, Katie L Kunze, et al.
Journal of Clinical Apheresis|April 5, 2014
Successful hematopoietic stem cell collection in patients who fail initial plerixafor mobilization for autologous stem cell transplantMuthu Veeraputhiran, Tania Jain, Simon Cronin, et al.
JMIR Research Protocols|July 31, 2019
An Online Mindfulness-Based Cognitive Behavioral Therapy Intervention for Youth Diagnosed With Major Depressive Disorders: Protocol for a Randomized Controlled TrialPaul Ritvo, Zafiris J Daskalakis, George Tomlinson, et al.
Leukemia Research|June 24, 2023
Co-occurring mutations in ASXL1, SRSF2, and SETBP1 define a subset of myelodysplastic/ myeloproliferative neoplasm with neutrophiliaTania Jain, Alisha D Ware, William Brian Dalton, et al.
Open Forum Infectious Diseases|June 6, 2022
Combination Therapy With Casirivimab/Imdevimab and Remdesivir for Protracted SARS-CoV-2 Infection in B-cell-Depleted PatientsM Veronica Dioverti, David C Gaston, C Paul Morris, et al.
Transplantation and Cellular Therapy|July 8, 2023
Updated Indications for Immune Effector Cell Therapy: 2023 Guidelines from the American Society for Transplantation and Cellular TherapyAbraham S Kanate, Navneet Majhail, Zachariah DeFilipp, et al.
Transplantation and Cellular Therapy|October 7, 2023
Proceedings of the 2023 Second Annual ASTCT-NMDP ACCESS Initiative WorkshopJeffery J Auletta, Jennifer Holter-Chakrabarty, Tania Jain, et al.
Future Oncology (London, England)|March 7, 2026
POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-naïve myelofibrosis patients with a suboptimal response to ruxolitinibPankit Vachhani, Abdulraheem Yacoub, Raajit Rampal, et al.
British Journal of Haematology|September 16, 2022
Hyperinflammatory syndrome resembling haemophagocytic lymphohistiocytosis following axicabtagene ciloleucel and brexucabtagene autoleucelTimothy J Porter, Ana Lazarevic, Jamie E Ziggas, et al.
Pageof 12

Showing results (41-50 of 118) with videos related to

Sort By:
Pageof 12
Clinical Lymphoma, Myeloma & Leukemia|July 14, 2015
BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple MyelomaMuthu Veeraputhiran, Tania Jain, Abhinav Deol, et al.
Leukemia & Lymphoma|April 14, 2020
Clinical outcomes with low dose anti-thymocyte globulin in patients undergoing matched unrelated donor allogeneic hematopoietic cell transplantationLuke Mountjoy, Tania Jain, Katie L Kunze, et al.
Journal of Clinical Apheresis|April 5, 2014
Successful hematopoietic stem cell collection in patients who fail initial plerixafor mobilization for autologous stem cell transplantMuthu Veeraputhiran, Tania Jain, Simon Cronin, et al.
JMIR Research Protocols|July 31, 2019
An Online Mindfulness-Based Cognitive Behavioral Therapy Intervention for Youth Diagnosed With Major Depressive Disorders: Protocol for a Randomized Controlled TrialPaul Ritvo, Zafiris J Daskalakis, George Tomlinson, et al.
Leukemia Research|June 24, 2023
Co-occurring mutations in ASXL1, SRSF2, and SETBP1 define a subset of myelodysplastic/ myeloproliferative neoplasm with neutrophiliaTania Jain, Alisha D Ware, William Brian Dalton, et al.
Open Forum Infectious Diseases|June 6, 2022
Combination Therapy With Casirivimab/Imdevimab and Remdesivir for Protracted SARS-CoV-2 Infection in B-cell-Depleted PatientsM Veronica Dioverti, David C Gaston, C Paul Morris, et al.
Transplantation and Cellular Therapy|July 8, 2023
Updated Indications for Immune Effector Cell Therapy: 2023 Guidelines from the American Society for Transplantation and Cellular TherapyAbraham S Kanate, Navneet Majhail, Zachariah DeFilipp, et al.
Transplantation and Cellular Therapy|October 7, 2023
Proceedings of the 2023 Second Annual ASTCT-NMDP ACCESS Initiative WorkshopJeffery J Auletta, Jennifer Holter-Chakrabarty, Tania Jain, et al.
Future Oncology (London, England)|March 7, 2026
POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-naïve myelofibrosis patients with a suboptimal response to ruxolitinibPankit Vachhani, Abdulraheem Yacoub, Raajit Rampal, et al.
British Journal of Haematology|September 16, 2022
Hyperinflammatory syndrome resembling haemophagocytic lymphohistiocytosis following axicabtagene ciloleucel and brexucabtagene autoleucelTimothy J Porter, Ana Lazarevic, Jamie E Ziggas, et al.
Pageof 12